WO2001049721A3 - Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations - Google Patents

Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations Download PDF

Info

Publication number
WO2001049721A3
WO2001049721A3 PCT/US2000/035604 US0035604W WO0149721A3 WO 2001049721 A3 WO2001049721 A3 WO 2001049721A3 US 0035604 W US0035604 W US 0035604W WO 0149721 A3 WO0149721 A3 WO 0149721A3
Authority
WO
WIPO (PCT)
Prior art keywords
essential
cell viability
proteins
bacterial genes
bacterial
Prior art date
Application number
PCT/US2000/035604
Other languages
English (en)
Other versions
WO2001049721A2 (fr
Inventor
Thomas J Dougherty
Michael J Pucci
Brian A Dougherty
Daniel B Davison
Robert E Bruccoleri
Jane A Thanassi
Original Assignee
Bristol Myers Squibb Co
Thomas J Dougherty
Michael J Pucci
Brian A Dougherty
Daniel B Davison
Robert E Bruccoleri
Jane A Thanassi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Thomas J Dougherty, Michael J Pucci, Brian A Dougherty, Daniel B Davison, Robert E Bruccoleri, Jane A Thanassi filed Critical Bristol Myers Squibb Co
Priority to EP00992297A priority Critical patent/EP1261630A2/fr
Priority to IL14947200A priority patent/IL149472A0/xx
Priority to AU43006/01A priority patent/AU4300601A/en
Priority to CA002396040A priority patent/CA2396040A1/fr
Publication of WO2001049721A2 publication Critical patent/WO2001049721A2/fr
Publication of WO2001049721A3 publication Critical patent/WO2001049721A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

La présente invention concerne de nouveaux gènes bactériens et leurs polypeptides codés qui sont essentiels pour la viabilité des cellules bactériennes, et leur utilisation.
PCT/US2000/035604 1999-12-30 2000-12-29 Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations WO2001049721A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00992297A EP1261630A2 (fr) 1999-12-30 2000-12-29 Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
IL14947200A IL149472A0 (en) 1999-12-30 2000-12-29 Nucleotide sequences and polypeptides encoded by the sequences that are essential for bacterial viability and methods for detecting and utilizing the same
AU43006/01A AU4300601A (en) 1999-12-30 2000-12-29 Novel bacterial genes and proteins that are essential for cell viability and their uses
CA002396040A CA2396040A1 (fr) 1999-12-30 2000-12-29 Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17408999P 1999-12-30 1999-12-30
US60/174,089 1999-12-30

Publications (2)

Publication Number Publication Date
WO2001049721A2 WO2001049721A2 (fr) 2001-07-12
WO2001049721A3 true WO2001049721A3 (fr) 2002-09-12

Family

ID=22634783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035604 WO2001049721A2 (fr) 1999-12-30 2000-12-29 Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1261630A2 (fr)
AU (1) AU4300601A (fr)
CA (1) CA2396040A1 (fr)
IL (1) IL149472A0 (fr)
WO (1) WO2001049721A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US6951729B1 (en) 1999-10-27 2005-10-04 Affinium Pharmaceuticals, Inc. High throughput screening method for biological agents affecting fatty acid biosynthesis
FR2807764B1 (fr) 2000-04-18 2004-09-10 Agronomique Inst Nat Rech Mutants de bacteries lactiques surproducteurs d'exopolysaccharides
US6830898B2 (en) 2000-08-24 2004-12-14 Omnigene Bioproducts, Inc. Microorganisms and assays for the identification of antibiotics
US6821746B2 (en) 2000-10-06 2004-11-23 Affinium Pharmaceuticals, Inc. Methods of screening for FabK antagonists and agonists
US7048926B2 (en) 2000-10-06 2006-05-23 Affinium Pharmaceuticals, Inc. Methods of agonizing and antagonizing FabK
US7056697B2 (en) 2000-10-06 2006-06-06 Affinium Pharmaceuticals, Inc. FabK variant
US7033795B2 (en) 2000-10-06 2006-04-25 Affinium Pharmaceuticals, Inc. FabK variant
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP2287314A1 (fr) 2003-03-04 2011-02-23 Intercell AG Antigènes pyogènes streptococcus
CA2522238A1 (fr) * 2003-04-15 2004-10-28 Intercell Ag Antigenes s-pneumoniae
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
CA2684873A1 (fr) 2007-05-22 2009-02-19 Wisconsin Alumni Research Foundation Ciblage des interfaces de maintenance du genome par des medicaments antibacteriens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018931A2 (fr) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Polynucleotides et sequences de streptococcus pneumoniae
WO1999033871A2 (fr) * 1997-12-31 1999-07-08 Millennium Pharmaceuticals, Inc. Genes bacteriens essentiels et leur utilisation
WO2000017644A1 (fr) * 1998-09-22 2000-03-30 Smithkline Beecham Corporation Ndp

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018931A2 (fr) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Polynucleotides et sequences de streptococcus pneumoniae
WO1999033871A2 (fr) * 1997-12-31 1999-07-08 Millennium Pharmaceuticals, Inc. Genes bacteriens essentiels et leur utilisation
WO2000017644A1 (fr) * 1998-09-22 2000-03-30 Smithkline Beecham Corporation Ndp

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRUCCOLERI R.E. ET AL.: "Concordance analysis of microbial genomes", NUCLEIC ACIDS RESEARCH., vol. 26, no. 19, 1998, OXFORD UNIVERSITY PRESS, SURREY., GB, pages 4482 - 4486, XP002178552, ISSN: 0305-1048 *
DE REUSE HILDE ET AL: "The Helicobacter pylori ureC gene codes for a phosphoglucosamine mutase.", JOURNAL OF BACTERIOLOGY, vol. 179, no. 11, June 1997 (1997-06-01), pages 3488 - 3493, XP002178549, ISSN: 0021-9193 *
GAGNON YVES ET AL: "Clustering and co-transcription of the Bacillus subtilis genes encoding the aminoacyl-tRNA synthetases specific for glutamate and for cysteine and the first enzyme for cysteine biosynthesis.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 10, 1994, US, pages 7473 - 7482, XP002178548, ISSN: 0021-9258 *
KAROW M ET AL: "THE ESSENTIAL ESCHERICHIA COLI MSBA GENE, A MULTICOPY SUPPRESSOR OF NULL MUTATIONS IN THE HTRB GENE, IS RELATED TO THE UNIVERSALLY CONSERVED FAMILY OF ATP-DEPENDENT TRANSLOCATORS", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 7, no. 1, January 1993 (1993-01-01), pages 69 - 79, XP002910304, ISSN: 0950-382X *
MADDOCK JANINE ET AL: "Identification of an essential Caulobacter crescentus gene encoding a member of the Obg family of GTP-binding proteins.", JOURNAL OF BACTERIOLOGY, vol. 179, no. 20, October 1997 (1997-10-01), pages 6426 - 6431, XP002178550, ISSN: 0021-9193 *
YAMADA K ET AL: "Novel properties of the Thermus thermophilus RuvB protein, which promotes branch migration of Holliday junctions.", MOLECULAR AND GENERAL GENETICS, vol. 261, no. 6, July 1999 (1999-07-01), pages 1001 - 1011, XP002178551, ISSN: 0026-8925 *
ZHANG Y-B ET AL: "Analysis of a Streptococcus pneumoniae gene encoding signal peptidase I and overproduction of the enzyme", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 194, no. 2, 31 July 1997 (1997-07-31), pages 249 - 255, XP004093351, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
WO2001049721A2 (fr) 2001-07-12
IL149472A0 (en) 2002-11-10
CA2396040A1 (fr) 2001-07-12
AU4300601A (en) 2001-07-16
EP1261630A2 (fr) 2002-12-04

Similar Documents

Publication Publication Date Title
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
WO2002002636A3 (fr) Proteine zupar i associee a une membrane
WO2001075067A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057188A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002031111A3 (fr) Acides nucleiques et polypeptides
WO2006083276A3 (fr) Polypeptides et conjugues interferon-alpha
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2004080148A3 (fr) Nouveaux acides nucleiques et polypeptides
AU4903101A (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2004046365A3 (fr) Polypeptides et conjugues interferon-alpha
WO2001049721A3 (fr) Nouveaux genes bacteriens et proteines qui sont essentielles pour la viabilite cellulaire et leurs utilisations
WO2001023412A3 (fr) Procedes de criblage d'agents inhibiteurs de l'agregation des polypeptides
WO2005047459A3 (fr) Acides nucleiques du sars, proteines, anticorps et utilisations associees
HK1045326A1 (zh) 微生物的β-葡萄糖甘酸酶基因，基因產品及其用法
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO1999020747A3 (fr) NOUVELLE KINASE HUMAINE POINT DE CONTROLE, hCDS1, COMPOSITIONS ET METHODES ASSOCIEES
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
WO2005049806A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002044340A3 (fr) Nouveaux acides nucleiques et polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 149472

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 43006/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000992297

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 550261

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2396040

Country of ref document: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000992297

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000992297

Country of ref document: EP